MeiraGTx (Nasdaq: MGTX), has announced two pre-clinical programs addressing Inherited Retinal Diseases (IRDs) caused by mutations in KCNV2 and GUCY2D, for cone-dystrophy, and are presented with… Read More »MeiraGTx (NASDAQ: MGTX), a UK gene therapy company, has announced two novel IRD research programs on gene therapy
An announcement from Bausch + Lomb and Clearside Biomedical have reported that the US FDA granted approval to triamcinolone acetonide injectable suspension (“XIPERE”) for suprachoroidal… Read More »Triamcinolone acetonide for suprachoroidal injection for treatment of uveitic macular oedema approves by the FDA.
Researchers, at the Henan Clinical Research Centre for Ophthalmic Diseases, Zhengzhou University, have reported a recent study identifying novel gene variants of the “REEP6” gene,… Read More »Three novel gene variants (REEP6) found within a population of autosomal recessive retinitis pigmentosa (arRP) patients
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the November 18th, 2021 edition of EURETINA’s web-based digital magazine,… Read More »November 18th, 2021: “EURETINA-Brief”© Issue No. 246
The US FDA has approved a 100 mg/mL ocular implant (Port Delivery System) for the treatment of nAMD, sponsored by Roche (SIX: RO, ROG; OTCQX:… Read More »FDA has approved an implant (Port Delivery System with ranibizumab) to treat neovascular age-related macular degeneration (nAMD)
Usher syndrome (USH) is a recessive disorder characterized by retinal degeneration and sensorineural hearing impairment with Usher syndrome type 2 (USH2) is the most frequent… Read More »A large cohort of Usher syndrome type 2 (USH2) patients with mutations in the ADGRV1 gene described key characteristics of functional and structural impairment
The researchers at the Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, have reported that the five visual function parameters commonly… Read More »Intermediate Age-Related Macular Degeneration (iAMD) has demonstrated useful comparisons between visual function tests within a research setting
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the November 3rd, 2021 edition of EURETINA’s web-based digital magazine,… Read More »November 3rd, 2021: “EURETINA-Brief”© Issue No. 245
Editas Medicine, Inc. (NASDAQ: EDIT) has announced positive initial clinical data from an ongoing, open label Phase I/II “BRILLIANCE” study EDIT-101, a CRISPR-based experimental treatment… Read More »Editas Medicine, Inc. (NASDAQ; EDIT) has announced positive clinical data on their CRISPR gene therapy product on LCA10
The US FDA (Food and Drug Administration) has approved authorisation for “Byooviz” (ranibizumab-nuna) as the first biosimilar to Lucentis (ranibizumab injection) “for the treatment of… Read More »FDA approval announces the first biosimilar in the USA for ranibizumab (Lucentis) intravitreal injection in neovascular AMD, RVO and myopic CNV